ClinicalTrials.gg
Not yet recruitingNCT05641220BIOPSYUpdated Dec 7, 2022

Biopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study.

An observational study in Glioblastoma, sponsored by Erasmus Medical Center. Not yet recruiting at 6 sites in Netherlands. Open to participants aged 70 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-12-07.

Sponsored by Erasmus Medical Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
325
Ages
70 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Glioblastoma with a site in Netherlands — 24 open to participants now, 33 under way, 5 of them phase 3. Glioblastoma · Netherlands.

Planned enrollment
8th of 15
325 · median 325
Started
2023
with 8 others
Observational
15 of 92
8 open now
Primary completion
2027-01
later than 10 of 32 live
Registered
67th of 92
by date
Lead sponsor
8 of 92
Erasmus Medical Center

Among the 92 studies in Glioblastoma with a site in Netherlands, this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 9 that started in 2023, is one of 15 observational ones, reaches primary completion later than 10 of the 32 other live ones, and was the 67th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

24 of the 92 studies in Glioblastoma with a site in Netherlands are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 70 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Glioblastoma with a site in Netherlands, or all of them as a file.
02

Study summary

This trial is set up as a prospective observational cohort study to identify if either biopsy or resection should be the surgical modality of choice in elderly glioblastoma patients with a newly diagnosed tumor. Patients who are considered eligible for GBM resection or biopsy will be included. Through shared-decision making patients and their treating physicians will decide upon resection or biopsy. Written informed consent will be obtained. Participants will be followed for 1 year postoperative to assess potential differences in health-related quality of life and overall survival.

Follow-up will consist of health-related quality of life questionaires and neurological assessment at 6 weeks, 3 months, 6 months and 12 months postoperative. Additionally Cognitive and neuro-linguistic tests will be done at 3 months postoperative. These will be compared to results pre-operative.

After surgery, patients will receive standard adjuvant treatment with concomitant Temozolomide and radiation therapy, and standard follow-up. Patients in whom the diagnosis GBM is not confirmed in histological analyses will be excluded from the study. Total study duration will be 4 years, of which 3 years will comprise patient inclusion, with a follow-up duration of 1 year.

03

Conditions studied

  • Glioblastoma

Keywords

  • Glioblastoma
  • High grade glioma
  • Surgical management
  • Biopsy
  • Resection
04

Who can participate

Ages eligible
70 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adults with presumed Glioblastoma on first diagnostic MRI-scan.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥70 years
  2. Tumor diagnosed as glioblastoma on MRI with distinct ring-like pattern of contrast enhancement with thick irregular walls and a core area reduced signal suggestive of tumor necrosis as assessed by the surgeon.
  3. Performance Score (KPS) ≥70
  4. Written

Exclusion criteria

Exclusion Criteria:

  1. Tumors of the cerebellum, brain stem or midline
  2. Multifocal contrast enhancing lesions
  3. Substantial non-contrast enhancing tumor areas suggesting low grade gliomas with malignant transformation
  4. Medical reasons precluding MRI (e.g. pacemaker)
  5. Inability to give consent as assessed by neurosurgeon (e.g. language barrier)
  6. Severe aphasia prohibiting neurolinguistic testing and comprehension of
  7. Previous brain tumor surgery
  8. Previous low-grade glioma
  9. Second primary within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
325 participants (estimated)
Patient registry
No

Groups and cohorts

  • Biopsy

    Newly diagnosed elderly (\>70 years of age) glioblastoma patients who undergo biopsy

  • Resection

    Newly diagnosed elderly (\>70 years of age) glioblastoma patients who undergo resection

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Defined as the time from diagnosis to the death of the patient from any cause

    Time frame: 12 months

  2. The difference in mean change score of physical functioning, as measured with the EORTC QLQ-C30 physical functioning scale, between the two groups at 6 weeks and 3 months after surgery compared to mean score on baseline

    Measured with the European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30), a higher scores means a worse outcome. We assume a minimally important difference of 7 between the 2 groups.

    Time frame: 6 weeks and 3 months after surgery

Secondary outcomes

  1. Progression-free survival (PFS), defined as the time from diagnosis to disease progression

    Increase in residual tumor volume of more than 25%, or occurrence of a new tumor lesion with a volume greater than 0.175cm3), or death. As according to the RANO criteria.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months after surgery

  2. The difference in mean change score of physical functioning, as measured with the EORTC QLQ-C30 physical functioning scale, between the two groups at 6 months and 12 months after surgery compared to mean score on baseline.

    Measured with the European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30), a higher scores means a worse outcome.

    Time frame: at 6 months and 12 months after surgery

  3. The proportion of patients with deterioration, improvement or stable physical functioning, as measured with the EORTC QLQ-C30 physical functioning scale at 6 weeks and 3 months compared to baseline.

    Measured with the European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30), a higher scores means a worse outcome.

    Time frame: 6 weeks and 3 months after surgery

  4. Descriptive reporting of changes in the mean scores on the other health-related quality of life (HRQoL) scales at 6 weeks and 3 months after surgery.

    HRQoL will be measured using the Measured with the European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30), EORTC , EORTC brain cancer module (QLQ-BN20) and EuroQol 5 Dimensions (EQ-5D) questionnaires. A higher scores means a worse outcome.

    Time frame: at 6 weeks and 3 months postoperative

  5. Proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration, improvement or stability at 6 weeks and 3 months after surgery

    In which deterioration is defined as an increase of at least one point and improvement as a decrease of at least one point on the total NIHSS score compared to this score at baseline.

    Time frame: at 6 weeks and 3 months postoperative

  6. Descriptive reporting of differences between the groups in cognitive and neuro-linguistic screening at 3 months compared to baseline.

    as measured by the Aphasia Bedside Check (ABC), Shortened Token Test, verbal fluency (category and letter), Montreal Cognitive Assessment (MOCA) and optionally CAT-NL Picture Description and Object Naming.

    Time frame: 3 months postoperative

  7. Comparison of the (S)AEs in both groups.

    Time frame: 6 weeks postoperative

  8. Cost-effectiveness between the two treatments.

    Measured as total intramural medical costs, for a 1 year time horizon

    Time frame: 12 months postoperative

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2023; primary completion for Jan 2027, 48 months later.

Of 85 non-industry observational studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 96. This study's planned 48 months is below that.

Counting every sponsor, half of 100 studies reached it within 52 months; a quarter within 33 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2022
First posted
Dec 7, 2022
StartEst.
Jan 1, 2023
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Dec 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05641220
Responsible party
A.J.P.E. VIncent (Prof. Dr., Erasmus Medical Center) — Principal investigator
First posted
Dec 7, 2022
Start date
Jan 1, 2023 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Dec 7, 2022

Study contacts

Yvette de Haan, drs
Contact
y.dehaan@erasmusmc.nl
+31612594000
Arnaud J.P.E. Vincent, Prof. Dr.
Contact
a.vincent@erasmusmc.nl
Arnaud J.P.E. Vincent, Prof. Dr.
principal investigator · Erasmus MC, department of neurosurgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion